Skin Conditions & Dermatology Clinical Trials Update: Week 44, 2026
Published October 30, 2026 — 5 trials covered
By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.
Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis
This Phase 4 trial led by Maastricht University Medical Center in the Netherlands studied a combination treatment of 5-Fluorouracil and Calcipotriol for actinic keratosis, a common skin condition caused by sun damage. The study compared this combination to the standard 5-Fluorouracil alone in 232 participants, aiming to see if the shorter, combined treatment could be just as effective while reducing side effects. The results will help guide future treatment choices and may offer patients a quicker and potentially easier therapy option.
A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL
HealthTech Wound Care is conducting a Phase 4 study on DermaBind TL, a placental membrane product designed to help heal chronic wounds like diabetic foot ulcers and venous leg ulcers. These types of ulcers can be difficult to treat and often last a long time, affecting quality of life. This trial, active in several US locations, follows patients over 13 weeks to see if DermaBind TL can improve healing rates and provide a new option for people living with these persistent wounds.
Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo
Cairo University is running a Phase 3 trial comparing two topical medicines, crisaborole and tacrolimus, each used with light therapy, for stable facial vitiligo. Vitiligo causes loss of skin color and can be challenging to treat. This study is recruiting children and adults in Egypt to find out which treatment better supports skin repigmentation and is well tolerated over six months of use. The findings could offer improved treatment strategies for those affected by this condition.
Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults
The National Cancer Institute is preparing a Phase 2 trial to test mirdametinib, an oral drug, for reducing large or giant congenital melanocytic nevi—large birthmarks present from birth. These birthmarks can sometimes lead to complications including skin cancer. This study plans to enroll participants aged 3 to 40 in the United States to evaluate if mirdametinib can safely shrink these nevi, potentially offering a new treatment option for affected young people and adults.
A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone
Tanta University in Egypt completed a Phase 2 trial comparing tacrolimus ointment and hydrocortisone cream for children with atopic dermatitis, a common form of eczema. This study included 100 children and aimed to determine which treatment more effectively reduces skin inflammation and symptoms. The results may help doctors and families choose the best topical medicine to manage this often itchy and uncomfortable condition in children.
TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.